ERBB2 and breast cancer: We hypothesized that nab-PTX would have a substantial effect on HER2-positive BC, and we subsequently found that the pCR (ypT0/is ypN0) rates were 63.5% for HER2-rich and 40.6% for luminal/HER2 subtypes.